These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20975274)

  • 1. Topiramate for the treatment of alcohol dependence: comparison with naltrexone.
    Flórez G; Saiz PA; García-Portilla P; Alvarez S; Nogueiras L; Bobes J
    Eur Addict Res; 2011; 17(1):29-36. PubMed ID: 20975274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using topiramate or naltrexone for the treatment of alcohol-dependent patients.
    Flórez G; García-Portilla P; Alvarez S; Saiz PA; Nogueiras L; Bobes J
    Alcohol Clin Exp Res; 2008 Jul; 32(7):1251-9. PubMed ID: 18482157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Amisulpride for the treatment of alcohol dependence].
    Flórez G; Saiz PA; García-Portilla P; Álvarez S; Nogueiras L; Bobes J
    Adicciones; 2011; 23(2):149-56. PubMed ID: 21647545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing topiramate with naltrexone in the treatment of alcohol dependence.
    Baltieri DA; Daró FR; Ribeiro PL; de Andrade AG
    Addiction; 2008 Dec; 103(12):2035-44. PubMed ID: 18855810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial.
    Johnson BA; Ait-Daoud N; Akhtar FZ; Ma JZ
    Arch Gen Psychiatry; 2004 Sep; 61(9):905-12. PubMed ID: 15351769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence.
    Laaksonen E; Koski-Jännes A; Salaspuro M; Ahtinen H; Alho H
    Alcohol Alcohol; 2008; 43(1):53-61. PubMed ID: 17965444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
    Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
    Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
    Falk D; Wang XQ; Liu L; Fertig J; Mattson M; Ryan M; Johnson B; Stout R; Litten RZ
    Alcohol Clin Exp Res; 2010 Dec; 34(12):2022-34. PubMed ID: 20659066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The state of pharmacotherapy for the treatment of alcohol dependence.
    Garbutt JC
    J Subst Abuse Treat; 2009 Jan; 36(1):S15-23; quiz S24-5. PubMed ID: 19062347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients.
    Baltieri DA; Daró FR; Ribeiro PL; Andrade AG
    Drug Alcohol Depend; 2009 Nov; 105(1-2):33-41. PubMed ID: 19595518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
    Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
    Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topiramate for alcohol dependence.
    Olmsted CL; Kockler DR
    Ann Pharmacother; 2008 Oct; 42(10):1475-80. PubMed ID: 18698008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
    O'Malley SS; Sinha R; Grilo CM; Capone C; Farren CK; McKee SA; Rounsaville BJ; Wu R
    Alcohol Clin Exp Res; 2007 Apr; 31(4):625-34. PubMed ID: 17374042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topiramate reduces the harm of excessive drinking: implications for public health and primary care.
    Ma JZ; Ait-Daoud N; Johnson BA
    Addiction; 2006 Nov; 101(11):1561-8. PubMed ID: 17034435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of alcoholic beverage preference in the severity of alcohol dependence and adherence to the treatment.
    Baltieri DA; Daró FR; Ribeiro PL; De Andrade AG
    Alcohol; 2009 May; 43(3):185-95. PubMed ID: 19269773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate in the treatment of alcohol dependence: a meta-analysis.
    Arbaizar B; Diersen-Sotos T; Gómez-Acebo I; Llorca J
    Actas Esp Psiquiatr; 2010; 38(1):8-12. PubMed ID: 20931405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial.
    Johnson BA; Rosenthal N; Capece JA; Wiegand F; Mao L; Beyers K; McKay A; Ait-Daoud N; Addolorato G; Anton RF; Ciraulo DA; Kranzler HR; Mann K; O'Malley SS; Swift RM; ;
    Arch Intern Med; 2008 Jun; 168(11):1188-99. PubMed ID: 18541827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism".
    Krystal JH; Gueorguieva R; Cramer J; Collins J; Rosenheck R;
    Alcohol Clin Exp Res; 2008 Jan; 32(1):85-91. PubMed ID: 18070245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
    Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
    JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.